Fluvastatin improves arterial stiffness in patients with coronary artery disease and hyperlipidemia - A 5-year follow-up study
Fluvastatin improves arterial stiffness in patients with coronary artery disease and hyperlipidemia - A 5-year follow-up study
复制标题
DOI：
10.1253/circj.72.722
复制
发表时间：
2008-05-01
影响因子：
3.3
通讯作者：
Ikeda, Uichi
中科院分区：
文献类型：
--
作者：
Hongo, Minoru;Tsutsui, Hiroshi;Ikeda, Uichi
本研究旨在验证氟伐他汀可能长期改善冠心病（CAD）和高脂血症患者动脉硬度的假设，以脉搏波速度（PWV）评估。方法与结果93例患者随机分为氟伐他汀组（A组，n=50）和贝扎布特组（B组，n=43），随访5年。两组患者的临床表现无明显差异。A组患者在氟伐他汀治疗12个月后，肱-踝PWV渐进式下降，血清低密度脂蛋白-胆固醇（LDL-C）和c反应蛋白（CRP）下降，并持续改善至治疗后5年。在第13组，尽管血脂水平同样降低，但PWV逐渐升高。A组PWV百分比变化与血清CRP百分比变化有显著相关性(r=0.49, p
Background The present study was designed to test the hypothesis that fluvastatin might improve arterial stiffness, as assessed with pulse wave velocity (PWV), in patients with coronary artery disease (CAD) and hyperlipidemia over the long term.Methods and Results Ninety-three patients were randomly assigned to either fluvastatin (group A, n=50) or bezafibrate (group B, n=43) and followed for 5 years. There was no difference in the clinical findings between the 2 groups. In group A, there was a progressive reduction in the brachial-ankle PWV along with a decrease in serum low-density lipoprotein-cholesterol (LDL-C) and C-reactive protein (CRP) by 12 months after fluvastatin, and the improvement was maintained until 5 years after treatment. In group 13, despite identical lowering of the serum lipid, PWV was progressively increased. In group A, the percentage change in PWV correlated significantly with that of the serum CRP (r=0.49, p